Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1991 4
1992 4
1993 4
1994 11
1995 15
1996 15
1997 25
1998 16
1999 19
2000 26
2001 18
2002 31
2003 26
2004 30
2005 29
2006 33
2007 39
2008 51
2009 30
2010 53
2011 52
2012 54
2013 80
2014 84
2015 80
2016 64
2017 61
2018 82
2019 84
2020 76
2021 67
2022 91
2023 74
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,240 results

Results by year

Filters applied: . Clear all
Page 1
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Ilic D, et al. BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519. BMJ. 2018. PMID: 30185521 Free PMC article.
OBJECTIVE: To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer. ...ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSA screeni …
OBJECTIVE: To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen fo …
Prostate Cancer in Primary Care.
Merriel SWD, Funston G, Hamilton W. Merriel SWD, et al. Adv Ther. 2018 Sep;35(9):1285-1294. doi: 10.1007/s12325-018-0766-1. Epub 2018 Aug 10. Adv Ther. 2018. PMID: 30097885 Free PMC article. Review.
Prostate cancer is a common malignancy seen worldwide. The incidence has risen in recent decades, mainly fuelled by more widespread use of prostate-specific antigen (PSA) testing, although prostate cancer mortality rates hav …
Prostate cancer is a common malignancy seen worldwide. The incidence has risen in recent decades, mainly fuelled by more wides …
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.
Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Van Poppel H, et al. Nat Rev Urol. 2022 Sep;19(9):562-572. doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16. Nat Rev Urol. 2022. PMID: 35974245 Review.
In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic prostate cancer and died of the disease; after the introduction of the serum PSA test, randomized controlled prostate cancer screening …
In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic prostate cancer and died …
The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.
Heijnsdijk EAM, Adolfsson J, Auvinen A, Roobol MJ, Hugosson J, de Koning HJ. Heijnsdijk EAM, et al. Eur Urol. 2019 Sep;76(3):276-279. doi: 10.1016/j.eururo.2019.04.007. Epub 2019 Apr 26. Eur Urol. 2019. PMID: 31031050 Free PMC article. Review.
The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 20% relative reduction in prostate cancer mortality after 16yr [rate ratio (RR) 0.80], but centers varied by attendance, screen interval, biopsy com …
The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 20% relative reduction in prostat …
Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.
Nam R, Patel C, Milot L, Hird A, Wallis C, Macinnis P, Singh M, Emmenegger U, Sherman C, Haider MA. Nam R, et al. BMJ Open. 2022 Nov 8;12(11):e059482. doi: 10.1136/bmjopen-2021-059482. BMJ Open. 2022. PMID: 36351725 Free PMC article. Clinical Trial.
OBJECTIVES: Our objective was to compare prostate cancer detection rates between patients undergoing serum prostate-specific antigen (PSA) vs magnetic resonance imaging (MRI) for prostate cancer screening. ...C …
OBJECTIVES: Our objective was to compare prostate cancer detection rates between patients undergoing serum prostate …
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S, Bangma CH, Godtman RA, Carlsson SV, Auvinen A, Tammela TLJ, Denis LJ, Nelen V, Villers A, Rebillard X, Kwiatkowski M, Recker F, Wyler S, Zappa M, Puliti D, Gorini G, Paez A, Lujan M, Nieboer D, Schröder FH, Roobol MJ. Remmers S, et al. Eur Urol. 2023 Nov;84(5):503-509. doi: 10.1016/j.eururo.2023.03.031. Epub 2023 Apr 21. Eur Urol. 2023. PMID: 37088597 Free PMC article. Clinical Trial.
BACKGROUND: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening based on the first prostate-specific antigen (PSA) level and age. ...PATIENT SUMMARY: In prostate ca …
BACKGROUND: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening …
Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
Paschen U, Sturtz S, Fleer D, Lampert U, Skoetz N, Dahm P. Paschen U, et al. BJU Int. 2022 Mar;129(3):280-289. doi: 10.1111/bju.15444. Epub 2021 Jul 7. BJU Int. 2022. PMID: 33961337 Review.
CONTEXT: Prostate-specific antigen (PSA) testing increases prostate cancer diagnoses and reduces long-term disease-specific mortality, but also results in overdiagnoses and treatment-related harms. ...PATIENT SUMMARY: In the presen …
CONTEXT: Prostate-specific antigen (PSA) testing increases prostate cancer diagnoses and reduces l …
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling F, Eklund M, Grönberg H; STHLM3 study group. Nordström T, et al. Lancet Oncol. 2021 Sep;22(9):1240-1249. doi: 10.1016/S1470-2045(21)00348-X. Epub 2021 Aug 13. Lancet Oncol. 2021. PMID: 34391509 Clinical Trial.
BACKGROUND: Screening for prostate cancer using prostate-specific antigen (PSA) reduces prostate cancer mortality but can lead to adverse outcomes. ...Combining the Stockholm3 test with an MRI-targeted biops …
BACKGROUND: Screening for prostate cancer using prostate-specific antigen (PSA) reduces …
Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study.
Mok Y, Kimm H, Shin SY, Jee SH, Platz EA. Mok Y, et al. Urology. 2015 May;85(5):1111-1116. doi: 10.1016/j.urology.2015.02.014. Urology. 2015. PMID: 25917733 Free PMC article.
OBJECTIVE: To evaluate the association between serum prostate-specific antigen (PSA) concentration from a screening test and prostate cancer mortality in an Asian population. ...CONCLUSION: In conclusion, an increased scr …
OBJECTIVE: To evaluate the association between serum prostate-specific antigen (PSA) concentration from a scr …
The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer.
Miller EA, Pinsky PF, Pierre-Victor D. Miller EA, et al. Cancer Causes Control. 2018 Oct;29(10):907-914. doi: 10.1007/s10552-018-1067-3. Epub 2018 Aug 9. Cancer Causes Control. 2018. PMID: 30094676
PURPOSE: Men with diabetes have been found to have a reduced risk of prostate cancer (PCa), potentially due to detection bias from lower prostate-specific antigen (PSA) levels or inhibition of tumor growth. Understanding if lower P …
PURPOSE: Men with diabetes have been found to have a reduced risk of prostate cancer (PCa), potentially due to detection …
1,240 results